I. Stasi

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini et al. · British Journal of Cancer · 2009 · 561 citations · Full text

Medicine, Genetics, Oncology +17

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

Fotios Loupakis, Luca Emanuele Pollina, I. Stasi et al. · Journal of Clinical Oncology · 2009 · 404 citations · Full text

Medicine, Oncology, Pharmacology +17

High Concordance of <i>KRAS</i> Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

Daniele Santini, Fotios Loupakis, Bruno Vincenzi et al. · The Oncologist · 2008 · 229 citations

Medicine, Oncology, Pathology +17

Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis

Gianluca Masi, E. Vasile, Fotios Loupakis et al. · JNCI Journal of the National Cancer Institute · 2010 · 189 citations

Medicine, Oncology, Chemotherapy +15

Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients

Fotios Loupakis, Chiara Cremolini, Gabriele Perrone et al. · Journal of Clinical Oncology · 2009 · 70 citations

Medicine, Oncology, Pharmacology +17